Search - tctmd.com

Displaying 1 - 20 of 62

Sort: Relevancy | Date

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

News Conference News EACTS 2025

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

Yael L. Maxwell

October 13, 2025

At EACTS 2024, Surgeons and Cardiologists Move Past EXCEL Firestorm

News Conference News EACTS 2024

At EACTS 2024, Surgeons and Cardiologists Move Past EXCEL Firestorm

Yael L. Maxwell

October 22, 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

News Conference News NY Valves 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

Michael O'Riordan

June 12, 2024

CASA-AF: Similar 3-Year Efficacy for Surgical and Catheter Ablation

News Conference News HRS 2024

CASA-AF: Similar 3-Year Efficacy for Surgical and Catheter Ablation

May 23, 2024

POLMIDES: Hybrid Revascularization Bests CABG For 10-Year Survival

News Conference News EuroPCR 2024

POLMIDES: Hybrid Revascularization Bests CABG For 10-Year Survival

Yael L. Maxwell

May 22, 2024

Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

News Conference News EuroPCR 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Michael O'Riordan

May 14, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

Isolated vs Concomitant SAVR Offer Similar 5-Year Outcomes: PARTNER 3

News Conference News STS 2024

Isolated vs Concomitant SAVR Offer Similar 5-Year Outcomes: PARTNER 3

Yael L. Maxwell

February 09, 2024

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

Surgeons Support Proposed Changes to Left Main CAD Guidelines

News Conference News EACTS 2023

Surgeons Support Proposed Changes to Left Main CAD Guidelines

Michael O'Riordan

October 13, 2023

AUTHEARTVISIT Reignites RCT vs Real-world Data Debate for AV Repair

News Conference News EACTS 2023

AUTHEARTVISIT Reignites RCT vs Real-world Data Debate for AV Repair

Michael O'Riordan

October 09, 2023

ESC/EACTS Task Force Recommends Downgrading PCI in Left Main CAD

News Conference News ESC 2023

ESC/EACTS Task Force Recommends Downgrading PCI in Left Main CAD

Michael O'Riordan

September 05, 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

March 05, 2023

In CABG/PCI Decisions for Left Main Disease, Diabetes ‘Still Matters’

News Conference News CRT 2023

In CABG/PCI Decisions for Left Main Disease, Diabetes ‘Still Matters’

Yael L. Maxwell

March 01, 2023

Surgeons Argue: STS Data Again Show ISCHEMIA Isn’t Definitive for CABG

News Conference News STS 2023

Surgeons Argue: STS Data Again Show ISCHEMIA Isn’t Definitive for CABG

Yael L. Maxwell

January 30, 2023

At STS 2023, Outgoing President’s Address Spurs Shock and Anger

News Conference News STS 2023

At STS 2023, Outgoing President’s Address Spurs Shock and Anger

Yael L. Maxwell

January 25, 2023

SCAAR Registry Delves Into Left Main Revascularization Outcomes

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

August 29, 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

News Conference News EuroPCR 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

Michael O'Riordan

May 23, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.